Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial.

Helium-oxygen therapy for infants with bronchiolitis: a randomized controlled trial.

Arch Pediatr Adolesc Med. 2011 Dec;165(12):1115-22

Authors: Kim IK, Phrampus E, Sikes K, Pendleton J, Saville A, Corcoran T, Gracely E, Venkataraman S

Abstract
OBJECTIVE: To compare nebulized racemic epinephrine delivered by 70% helium and 30% oxygen or 100% oxygen followed by helium-oxygen inhalation therapy via high-flow nasal cannula (HFNC) vs oxygen inhalation via HFNC in the treatment of bronchiolitis.
DESIGN: Prospective, randomized, controlled, single-blind trial.
SETTING: This study was conducted from October 1, 2004, through May 31, 2008, in the emergency department of an urban, tertiary care children’s hospital. Patients  Infants aged 2 to 12 months with a Modified Wood’s Clinical Asthma Score (M-WCAS) of 3 or higher.
INTERVENTIONS: Patients initially received nebulized albuterol treatment driven by 100% oxygen. Patients were randomized to the helium-oxygen or oxygen group and received nebulized racemic epinephrine via a face mask. After nebulization, humidified helium-oxygen or oxygen was delivered by HFNC. After 60 minutes of inhalation therapy, patients with an M-WCAS of 2 or higher received a second delivery of nebulized racemic epinephrine followed by helium-oxygen or oxygen delivered by HFNC. Main Outcome Measure  Degree of improvement of M-WCAS for 240 minutes or until emergency department discharge.
RESULTS: Of 69 infants enrolled, 34 were randomized to the helium-oxygen group and 35 to the oxygen group. The mean change in M-WCAS from baseline to 240 minutes or emergency department discharge was 1.84 for the helium-oxygen group compared with 0.31 for the oxygen group (P < .001). The mean M-WCAS was significantly improved for the helium-oxygen group compared with the oxygen group at 60 minutes (P = .005), 120 minutes (P < .001), 180 minutes (P < .001), and 240 minutes (P < .001).
CONCLUSION: Nebulized racemic epinephrine delivered by helium-oxygen followed by helium-oxygen inhalation therapy delivered by HFNC was associated with a greater degree of clinical improvement compared with that delivered by oxygen among infants with bronchiolitis. Trial Registration  clinicaltrials.gov Identifier: NCT00116584.

PMID: 22147778 [PubMed – in process]

View full post on pubmed: asthma

Acton Pharma Says Trial Of Asthma Therapy Aerospan Shows No Growth Suppression – RTT News

Acton Pharma Says Trial Of Asthma Therapy Aerospan Shows No Growth Suppression
RTT News
(RTTNews) – Privately-held Acton Pharmaceuticals Inc. Tuesday reported the publication of results of the Phase IIIb trial of Aerospan, a long-term asthma therapy, which said no suppression of growth and bone maturation was found in prepubescent
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide MarketWatch (press release)

all 4 news articles »

View full post on asthma – Google News

Mutant genes found for asthma, point to possible therapy – Reuters

Mutant genes found for asthma, point to possible therapy
Reuters
HONG KONG (Reuters) – A drug used to treat rheumatoid arthritis could help asthma patients, scientists said on Friday, as they identified two mutant genes that may predispose a person to asthma. Over 235 million people worldwide suffer
Asthma genetics discovery made in QueenslandMy Sunshine Coast (press release)

all 6 news articles »

View full post on asthma – Google News

Leukotriene antagonists for first-line or add-on asthma therapy – American Pharmacists Association, pharmacist.com

Leukotriene antagonists for first-line or add-on asthma therapy
American Pharmacists Association, pharmacist.com
Key point: In patients with asthma, leukotriene-receptor antagonists (LTRAs) managed the disease just as successfully as inhaled glucocorticoid for first-line therapy or long-acting beta-2 agonist as add-on therapy. Finer points: Two parallel,

View full post on asthma – Google News

Minivectors renew gene therapy hopes for lung cancer and asthma treatments – Next Big Future

Minivectors renew gene therapy hopes for lung cancer and asthma treatments
Next Big Future
The ability to get deep in the lungs means that the Minivectors could be a potential treatment for a host of lung diseases, including lung cancer and asthma. These Minivectors, developed in the laboratory of Dr. Lynn Zechiedrich, associate professor of

View full post on asthma – Google News

Experts to develop pioneering tool for personalised asthma and COPD therapy – News-Medical.net

Experts to develop pioneering tool for personalised asthma and COPD therapy
News-Medical.net
A team of international experts, led by a University of Leicester researcher based at Glenfield Hospital, is set to develop a pioneering tool to help tailor the treatment of asthma and chronic obstructive pulmonary disease (COPD) as part of a new EU

and more »

View full post on asthma – Google News

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy – Medical News Today (press release)

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
Medical News Today (press release)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the

and more »

View full post on asthma – Google News